We’re proud to announce that patient recruitment is now underway at Sydney’s Royal North Shore Hospital for our pivotal clinical trial of the Oli PPH Early Warning System.
Director of Clinical Operations, Bernadette Pickering, stated “This trial marks a major step towards bringing Oli to the patients and clinicians who need it most. We are thrilled to kick off recruitment with the incredible clinicians at RNSH. Our team has worked tirelessly to reach this point—building and rigorously testing the system, and working with our world-class clinical and regulatory partners to commence this crucial study.”
The Oli-PPH product is the inaugural capability of the Oli maternal and fetal monitoring system and provides early warning for postpartum hemorrhage, a condition that affects 14 million births per year* and is the leading cause of preventable maternal death worldwide. Oli’s warning at least one hour prior to birth that a hemorrhage is likely to take place, provides clinicians with the gift of time to prepare for and treat this potentially life-threatening complication. This study represents a major milestone for the Oli-PPH early warning system prior to submitting the product for regulatory clearance, and preparing for commercial launch.
A heartfelt thank you to our research partners, clinical teams, investors, and supporters who are helping make this vision a reality.
We’re looking forward to sharing updates as the trial progresses—and to taking one step closer to making pregnancy and childbirth safer for mothers and babies.
